ABUS vs GSK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABUS and GSK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABUS and GSK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Arbutus Biopharma is a clinical-stage biopharmaceutical company that leverages deep virology expertise to develop novel therapeutics aimed at a functional cure for chronic hepatitis B virus (cHBV), a disease affecting hundreds of millions of people worldwide for which current treatments rarely cure. Its lead candidate is imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNAi (RNA interference) therapeutic designed to suppress all HBV antigens, including surface antigen (HBsAg), and it is being studied in combination regimens. Arbutus has reported that a number of patients across its Phase 2a IM-PROVE trials achieved a functional cure when imdusiran was combined with standard antivirals plus agents like pegylated interferon or low-dose immunotherapy, and in 2026 the FDA granted imdusiran Fast Track designation. A second candidate, AB-101, is an oral PD-L1 inhibitor in early clinical testing meant to reawaken the immune response against HBV.

Full ABUS guide

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. It reorganized in 2022 when it spun off its consumer health arm as Haleon, leaving GSK as a pure biopharma business. Its most durable franchises are vaccines, led by the shingles vaccine Shingrix and the newer RSV vaccine Arexvy, and HIV, which it manages largely through the ViiV Healthcare joint venture with a shift toward long-acting injectable regimens. It also has growing positions in respiratory, immunology and inflammation, and oncology.

Full GSK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABUS drivers: Imdusiran functional-cure program; Moderna settlement and cash.
• GSK drivers: Vaccines franchise durability; HIV and long-acting injectables.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. For GSK, the central risk is the patent cliff and pipeline dependence: maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABUS if you believe its drivers more; GSK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABUS and GSK guides.

ABUS. These figures are approximate and tied to the Jul 2026 asOf date; verify live trial status, settlement terms and receipts, and cash figures against Arbutus's latest quarterly filings before acting. Traditional valuation multiples do not apply cleanly to a pre-revenue biotech: the stock is driven by clinical data, regulatory milestones, and, unusually here, the litigation settlement cash, so earnings snapshots are less meaningful than pipeline progress and balance-sheet strength.

GSK. These figures are approximate, tied to the asOf date, and reported in a mix of pounds and dollars because GSK is a UK company trading as a US ADR, so verify live numbers before acting. GSK's lower multiple reflects slower growth and pipeline and litigation overhangs rather than a distressed balance sheet. The stock tends to behave like a value-and-income pharma holding, so the multiple matters less than whether new launches can offset patent expiries over time.

Headline figures (approximate, Jul 2026): ABUS shows stage Clinical-stage biotech; no meaningful product revenue, lead asset Imdusiran (AB-729), RNAi for chronic hepatitis B, Phase 2a, FDA Fast Track, second asset AB-101, oral PD-L1 inhibitor, early clinical, moderna settlement $2.25B global settlement (noncontingent ~$950M plus ~$1.3B contingent); Arbutus expects ~$178.7M share in mid-2026 (verify live); GSK shows revenue (ttm) approximately £31 to £32 billion, with vaccines, HIV, and specialty medicines the main contributors, operating margin reported around the mid-to-high 20s percent on an adjusted basis, typical of large-cap pharma, eps adjusted earnings per share reported in roughly the mid-single-digit dollars per ADR; verify the latest figure live, market cap approximately $105 to $110 billion (ADR traded around the low $50s in early 2026).

ABUS and GSK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABUS and GSK exposure against your real portfolio. It is not an investment adviser.